Program
sparsentan
Also written as “Sparsentan”, “PS433540” and “RE-021 (Sparsentan)”.
Its studies are mostly in Glomerulosclerosis, Focal Segmental · Glomerulonephritis, IGA · Hypertension · Proteinuria, led by 2 companies.
Drug pageSparsentan: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Travere Therapeuticsits history only | 72 open or running | phase 4since Oct 9, 2025 | Jun 4, 2012 | Mar 2027phase 4 · NCT07219121 |
| Ligand Pharmaceuticals | 20 open or running | phase 2since Aug 29, 2007 | Aug 29, 2007 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Ligand Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 29, 2007First study: phase 2 study in HypertensionFirst studyNCT00522925 · 280 enrolled · United States
- Mar 6, 2008Phase 2 study in HypertensionNCT00635232 · 261 enrolled · United States
- Jun 9, 2015Named sparsentanINNProposed as its International Nonproprietary Name in WHO's List 113 · before, PS433540
TargetBeta
“Endothelin receptor ET-A antagonist; Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Studies
All 2 Ligand Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00635232Hypertension · United States | 2 | Completed | Nov 2008 | 261 |
| NCT00522925Hypertension · United States | 2 | Completed | Apr 2008 | 280 |
How it is read
Names in the registry
- “Sparsentan”, 5 entries
- “PS433540”, 5 entries
- “sparsentan”, 2 entries
- “RE-021 (Sparsentan)”, 1 entry
- “RE-021, sparsentan”, 1 entry
Conditions, from the studies’ own filings
- Glomerulosclerosis, Focal Segmental, 4 studies
- Glomerulonephritis, IGA, 2 studies
- Hypertension, 2 studies
- Proteinuria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.